CellaVision (CEVI.ST) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Market Cap: $313.0MFounded: 2026Employees: 250-300HQ: Lund, Sweden

Sector Ranking#51 in Diagnostics & Precision Medicine #9 in AI / Machine Learning

Overview

CellaVision is a global leader in digital hematology microscopy, founded in 1994 with a mission to automate and standardize manual blood cell analysis. The company has achieved a dominant position with over 8,000 units installed in more than 40 countries, driven by its integrated platform of instruments, reagents, and AI-enhanced software. Its strategy focuses on continuous innovation to expand its solution ecosystem, deepen laboratory workflow integration, and leverage artificial intelligence to solidify its standard-of-care status in clinical laboratories worldwide.

HematologyOncology

Technology Platform

Integrated Digital Cell Morphology (DCM) platform combining high-resolution digital microscopy, proprietary image analysis algorithms, and AI for the automated pre-classification and review of blood and body fluid cells.

Funding History

2

IPOUndisclosedUndisclosedJun 15, 2007

Opportunities

The launch of the Bone Marrow Aspirate Application opens a significant new market segment in specialized hematology/oncology labs.

Continued global laboratory staff shortages and the push for digitalization and standardization provide strong tailwinds for automating manual microscopy workflows.

Leveraging its large installed base for recurring reagent sales and software upgrades offers a stable growth foundation.

Risk Factors

Growth is dependent on expanding into new markets (geographic and sample-type) as core markets mature.

Faces competition from large integrated hematology vendors who can bundle solutions.

Concentrated reagent manufacturing and outsourced instrument assembly create supply chain vulnerabilities.

Competitive Landscape

Dominant leader in digital cell morphology, competing primarily against manual microscopy and integrated modules from large hematology analyzer vendors (e.g., Sysmex). Maintains a strong moat through its installed base, proprietary AI algorithms, and complete workflow ecosystem, but must continuously innovate to defend against competitive bundling and potential software-only AI disruptors.